Imunon's second quarter 2026 loss of $0.54 per share beat estimates with $1.5M R&D spend

Imunon reported a narrower-than-expected net loss of $2.8 million for the second quarter of 2026, driven by disciplined R&D spending even as clinical activities accelerated. The company highlighted rapid enrollment in its pivotal Phase 3 OVATION 3 trial and positive preliminary data from its Phase 2 minimal residual disease study.

Key Highlights

• Reported a net loss of $0.54 per share, significantly outperforming the analyst estimate of a $0.94 loss.
• Research and development expenses were $1.5 million, well below the $4.2 million estimate, despite the initiation of the Phase 3 OVATION 3 study.
• Liquidity was bolstered by a $10 million financing agreement in June 2026, ending the quarter with $6.9 million in cash and cash equivalents.